Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROCKET-Outpost: Self-administered subcutaneous rocatinlimab in moderate-to-severe atopic dermatitis
jRCT2051240013Phase 3Completed
- Sponsor
- Amgen
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of rocatinlimab in atopic dermatitis (AD) (3 arms), sponsored by Amgen. Primary endpoint: Proportion of Full-dose Self-administered Rocatinlimab Injections Among Attempted Home-use Injections up to Week 16. Started Sep 2024; status: completed.
02
Drugs
rocatinlimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2051240013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240013.